Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
This trial is active, not recruiting.
|Condition||carcinoma, non-small-cell lung|
|Sponsor||Fox Chase Cancer Center|
|Start date||March 2007|
|End date||October 2013|
|Trial size||33 participants|
|Trial identifier||NCT00553800, FER-TH-007|
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Galloway, NJ||AtlantiCare Regional Medical Center||no longer recruiting|
|Mount Holly, NJ||Fox Chase Virtua Health Cancer Program at Memorial||no longer recruiting|
|Paoli, PA||Paoli Hospital||no longer recruiting|
|Philadelphia, PA||Abramson Cnacer Center, University of Pennsylvania||no longer recruiting|
|Philadelphia, PA||Pennsylvania Oncology Hematology Associates||no longer recruiting|
|Philadelphia, PA||Fox Chase Cancer Center||no longer recruiting|
|Sellersville, PA||Grand View Hospital||no longer recruiting|
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
bevacizumab 15 mg/kg intravenous every three weeks and erlotinib pill 150 mg by mouth every day
Efficacy measure is progression free survival defined as the time from enrollment to documented progression of disease by radiologic imaging.
time frame: Scans to be done after every 2nd cycle of treatment
time frame: every 3 weeks at day 1 physician exam and in between as needed
Male or female participants at least 70 years old.
Inclusion Criteria: - Cytologically or histologic confirmed non-small cell lung cancer, stage IIIB or IV or recurrent after primary surgery or radiotherapy. - ECOG PS 0-1 - 70 years of age or older - Must have measurable disease - ANC > 1500, platelets > 100,000 - Total bilirubin = 1.5, SGOT * SGPT < 5 x ULN - Able and willing to swallow and absorb oral medication - Able and willing to sign consent - Request archival diagnostic tissue for EGFR expression but not required Exclusion Criteria: - Proteinuria as demonstrated by UPC ratio >/= 1.0 - Prior treatment with an investigational or marketed inhibitor of the EGFR pathway or anti-angiogenesis agent (includes thalidomide) - Prior treatment for advanced stage disease, with the exception of surgery or radiation (no systemic) - History of gross hemoptysis within 1 month of enrollment unless treated with surgery or radiation - Evidence of bleeding diathesis or coagulopathy or other serious/acute internal bleeding within 6 months of enrollment. - Current, ongoing treatment with full dose warfarin or equivalent - Current(within 10 days)use of aspirin (> 325mg/day) or other NSAID with antiplatelet activity - History of hemorrhagic or thrombotic stoke, TIA, or other CNS bleeding w/in last 6 months. Clinically significant PVD - Known CNS disease except for treated brain mets. - Squamous cell histology - Blood pressure > 150/100 that cannot be ameliorated with standard anti-hypertensives - History of hypertensive crisis or hypertensive encephalopathy - NYHA grade II or > CHF - History of MI within 6 months of enrollment - Major surgery, open biopsy, significant trauma within 28 days of enrollment - Pregnancy, lactation - Abdominal or other fistula, abcess, perforation
|Official title||Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer|
|Principal investigator||Hossein Borghaei, DO|
|Description||There is no definite evidence of a superior therapy for advanced non-small cell lung cancer in elderly patients. With the exception of one known study, single agent erlotinib has not been studied exclusively in the elderly and the combination of erlotinib and bevacizumab has never been studied exclusively in the treatment naive elderly. This is an important population that needs less toxic therapies.|
Call for more information